7-oxo-DHEA and Raynaud's phenomenon.
Patients with Raynaud's phenomenon have abnormal digital vasoconstriction in response to cold. The pathogenesis remains unknown but may involve a local neurovascular defect leading to vasoconstriction. Diagnosis of primary Raynaud's phenomenon is based on typical symptomatology coupled with normal physical examination, normal laboratory studies and lack of observable pathology by nail fold capillaroscopy. Secondary Raynaud's phenomenon is known to occur associated with several connective tissue diseases, vascular injury due to repeated vibrational trauma, and other causes which produce demonstrable vascular and microcirculatory damage. Treatment of Raynaud's symptoms is conservative and aimed at prevention of attacks. Patients are advised to remain warm and, if possible, to live in warm climates. We suggest that an ergogenic (thermogenic) steroid, 7-oxo-DHEA (3-acetoxyandrost-5-ene-7,17-dione), which is available without prescription as the trademarked 7-keto DHEA, may be very helpful in prevention of primary Raynaud's attacks by increasing the basal metabolic rate and inhibiting vasospasm.
Ihler
Garret
G
Department of Medical Biochemistry and Medical Genetics, Texas A&M College of Medicine, College Station 77843, USA. gmihler@tamu.edu
Chami-Stemmann
Hasna
H
D002986:Clinical Trials as Topic; D003687:Dehydroepiandrosterone / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D006801:Humans; D008962:Models, Theoretical; D011928:Raynaud Disease / Q000175:diagnosis* / Q000517:prevention & control / Q000628:therapy; D013256:Steroids / Q000378:metabolism; D022722:Thermogenesis; D014284:Triiodothyronine / Q000378:metabolism
D013256:Steroids; D014284:Triiodothyronine; D003687:Dehydroepiandrosterone; C117281:3-acetoxyandrost-5-ene-7,17-dione